Comparative pharmacodynamics of Ro 41-3696, a new hypnotic, and zolpidem after night-time administration to healthy subjects
- 26 Downloads
In a double-blind, six-way crossover study the effects on psychomotor performance and memory of single doses of Ro 41-3696 (1, 3, 5 and 10 mg), a novel non-benzodiazepine partial agonist at the benzodiazepine receptor, zolpidem (10 mg) and placebo were compared after night-time administration to 12 healthy young male subjects. Psychomotor performance tests (tracking and attention as part of a standardized task battery) were conducted just before and at 1.5 and 8 h after drug intake. The memory test consisted of the recall of a list of 15 words at 8 h after drug intake which had been learned at 1.5 h after intake. At 1.5 h after drug intake 10 mg zolpidem induced markedly larger psychomotor effects than any dose of Ro 41-3696. The effects of 5 and 10 mg Ro 41-3696 and zolpidem were significantly greater than those of placebo (P < 0.05). The following morning, 8 h after drug intake, the slight residual effects of 5 and 10 mg Ro 41-3696 were statistically significantly greater than placebo, whereas zolpidem effects did not differ from placebo. The results of the memory test showed that learning as well as recall were most clearly impaired by zolpidem. An influence of Ro 41-3696 on these variables was not observed for doses up to 5 mg. In conclusion, Ro 41-3696 at all doses tested induced less effects on psychomotor performance and memory than 10 mg zolpidem at 1.5 h after intake. However, the effects of Ro 41-3696 appeared to be of longer duration.
Key wordsRo 41-3696 Zolpidem Psychomotor performance Memory Hypnotics Pharmacodynamics
Unable to display preview. Download preview PDF.
- Boer LC, Wientjes CJE (1988) Assessment of psychological fitness. In: Aschenbrenner H (ed) Proceedings of the workshop on psychological fitness. NATO DS/A/DR 89:107, pp 1–11Google Scholar
- Dingemanse J, Bury M, Roncari G, Zell M, Gieschke R, Gaillard AWK, Odink J, Van Brummelen P (1995) Pharmacokinetics and pharmacodynamics of Ro 41-3696, a novel non-benzodiazepine hypnotic. J Clin Pharmacol: (in press)Google Scholar
- ECSC-EEC-EAEC (1994) Guidelines on psychotropic drugs for the EC. Eur Neuropsychopharmacol 4:61–77Google Scholar
- Hindmarch I (1991) Residual effects of hypnotics: an update. J Clin Psychiatry 52 [Suppl]: 14–15Google Scholar
- Jonas JM, Coleman BS, Sheridan AQ, Kalinske RW (1992) Comparative clinical profiles of triazolam versus other shorteracting hypnotics. J Clin Psychiatry 53 [12 Suppl.]: 19–31Google Scholar
- Langer SZ, Arbilla S, Scatton B, Niddam R, Dubois A (1988) Receptors involved in the mechanism of action of zolpidem. In: Sauvanet JP, Langer SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 55–80Google Scholar
- Lorizio A, Terzano MG, Parrino L, Cesana BM, Priore P (1990) Zolpidem: a double-blind comparison of the hypnotic activity and safety of a 10-mg versus 20-mg dose. Curr Ther Res 47:889–898Google Scholar
- Martin JR, Moreau J-L, Jenck F, Widmer U (1994) Pharmacological profile of several quinolizinones acting as partial agonists at the benzodiazepine receptor. Neuropsychopharmacology 10, 3S [Part 2]: 170SGoogle Scholar
- Scherschlicht R (1994) The quinolizinone hypnotic Ro 41-3696, a partial agonist at the flumazenil binding site, induces EEG sleep in rabbits but lacks sedative side effects in rodents. 8. Biennial IPEG meeting, Berlin, GermanyGoogle Scholar
- Sternberg S (1969) Mental processes revealed by reaction time experiments. Am Sci 4:421–457Google Scholar